A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: VIR BIOTECHNOLOGY INC.
- Phase: III
- Execution start: 30/10/2020
- End of execution: 30/06/2021
- PI: JUAN PASQUAU LIAÑO